initial public offerings (IPOs) trading on American exchanges

Saturday, September 30, 2017

Voxeljet (VJET) : 4-year performance

  


Roku (ROKU) started trading on the Nasdaq on 28 Sept 2017

  • After pricing its IPO Wednesday at $14 per share, Roku finished its first day of trading at $23.50, up nearly 68 percent. And by the end of Friday, Roku closed at $26.54. 
  • The company is now valued at about $2.6 billion.




Description

Roku, Inc. is a United States-based company engaged in creating streaming platform for delivering entertainment to the television. The Company’s products include Roku 4, Roku 3, Roku 2, Roku 1, Roku Streaming Stick and accessories, such as cables, remote controls, power adapters and headphones. Its Roku streaming players and the Roku Streaming Stick are sold through retailers in the United States, Canada, the United Kingdom, the Republic of Ireland, Mexico and France. It licenses a reference design and operating system to television manufacturers to create co-branded Roku TV models. Under the Roku Powered program, it licenses its streaming platform to pay television providers who want to use the Internet to deliver entertainment services through streaming players. It sells Roku streaming players in retail, through its licensing arrangements with television original equipment manufacturers and pay television operators.

Address

12980 Saratoga Ave Ste D
SARATOGA, CA 95070-4659
United States 

Key stats and ratios

Q2 (Jun '17)2016
Net profit margin-15.57%-10.73%
Operating margin-13.43%-10.88%
EBITD margin--9.63%
Return on average assets-34.84%-24.05%
Return on average equity--
Employees696

Thursday, September 28, 2017

Gold Standard Ventures (GSV) : to commence Drilling at the Lewis Project, Battle Mountain District, Nevada

Headquarters: Vancouver, Canada
Founded: 2004
goldstandardv.com

 

  







Gold Standard Ventures will commence a drill program in mid-October at its 100%-owned Lewis Project in the Battle Mountain mining district, Lander County, Nevada
Highlights
  • Completing core hole BVM16C-03B which was suspended due to adverse weather conditions in January, 2017. The hole was halted in visually-encouraging alteration above the targeted permissive host formations (Antler Sequence).
  • Site MGH-F will test for the down-dip extension of the Phoenix deposit which has the potential for high grade gold-silver deposits in Antler Peak Limestone similar to the adjacent Lower Fortitude deposit that produced 1.9 moz of gold and 7.5 moz of silver at an average grade of 8 g/t gold and 32 g/t silver. {See Cary, et al., 2000, Geology, skarn alteration, and Au-Cu-Ag mineralization of the Phoenix project, (Battle Mountain mining district), Lander County, Nevada, in Cluer, J.K., Price, J.G., Struhsacker, E.M., Hardyman, R.F., and Morris, C.L., eds., Geology and Ore Deposits 2000: The Great Basin and Beyond: Geological Society of Nevada, Symposium Proceedings, May 15-18, 2000, p. 1021-1045. (See Table 1)}
  • One RC precollar/core tail hole is planned in the Southwest target area to offset by 300 m a 17 m skarn intercept drilled by Barrick Gold grading 5.7 g/t Au (from 776 to 793 m in FWL-30 using a 2.5 g/t cutoff). The bottom of this interval has 4.6 meters of 9 g/t Au and 21 g/t Ag. This hole will also test for Fortitude-style gold mineralization in Antler Peak Limestone.

Zynerba Pharma (ZYNE) : positive results of cannabidiol (CBD) gel in pediatric and adolescent patients with Fragile X syndrome

  •  Sector(s): Healthcare
  • Industry: Drug Manufacturers—Specialty & Generic
  • Full Time Employees: 28
  • Founded in 2007 
  • Headquartered in Devon, Pennsylvania
  • http://zynerba.com






Zynerba Pharma announces 'positive' top line results from an open label exploratory Phase 2 FAB-C clinical trial evaluating ZYN002 cannabidiol (CBD) gel in pediatric and adolescent patients with Fragile X syndrome
ZYN002 successfully met the primary endpoint and showed clinically 'meaningful improvements'
  • ZYN002 also achieved clinically meaningful improvements in all measures of the Aberrant Behavior Checklist for Fragile X (ABC-FXS), which address the key symptoms of FXS including social avoidance, temper tantrums, repetitive movements, and hyperactivity.
  • "The data from the FAB-C trial are very exciting and demonstrate that ZYN002 may have a profound effect on improving many of the most disabling symptoms of Fragile X, such as anxiety and difficult behaviors."
  • With these data, Zynerba anticipates that it will meet with the FDA in the first half of 2018 with the goal of moving quickly into a pivotal Phase 2/3 program in pediatric and adolescent patients with FXS in 2018.

** charts before  **

 



Friday, September 22, 2017

Audentes Therapeutics (BOLD) started trading on the Nasdaq on 19 July 2016

Audentes is one of the leaders in the nascent field of gene therapy, using an adeno-associated virus, or AAV, vector to carry a healthy copy of a gene into a cell. The viral vectors essentially are vehicles, modified so they aren't infectious but can slip past a cell's normal defenses to deliver the healthy gene.

Audentes sold 5 million shares at $15 apiece in its IPO. The $75 million raise will help Audentes fund clinical work it’s doing on rare diseases such as X-Linked myotubular myopathy, Crigler-Najjar Syndrome, and Pompe disease.



Description

Audentes Therapeutics, Inc. is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT). The Company's subsidiary is Audentes Therapeutics UK Ltd. As of September 30, 2016, the Company had not generated any revenues.

Key stats and ratios

Q2 (Jun '17)2016
Net profit margin--
Operating margin--
EBITD margin--
Return on average assets-58.78%-45.98%
Return on average equity-68.94%-139.89%
Employees97

Secoo (SECO) started trading on the Nasdaq on 22 Sept 2017

Secoo prices its IPO of 8,500,000 American depositary shares at a price to the public of $13.00/ADS vs. expected range of $11.50-13.50, for a total offering size of approx. $110.50 mln




WASHINGTON, Sept 21 (Reuters Breakingviews) - A Chinese e-commerce startup is sitting in the lap of IPO luxury. Secoo has carved out a niche for itself in a cutthroat market, selling upscale brands such as Tod's and Versace. Though it's burning cash, the American depository shares on offer have a certain allure.
Secoo's customer base is smaller. Despite boasting some 15 million registered users, only 200,000 of them made at least one purchase during the first half of 2017. Yoox counted more than 3 million.
The Chinese firm nevertheless has its advantages. For one thing, Secoo customers aren't shy about spending. Average sales per order online was $516, more than $100 higher than at Yoox. Secoo also boasts some distinctly local edges. It caters specifically to posh tastes. That distinguishes it from the sprawling wares at larger rivals Alibaba and JD.com. Secoo also has yet to get tangled up in a counterfeit dispute.
Because Secoo has been losing money, albeit less of it than in previous years, traditional valuation methods are difficult. Based on its mooted price range, it would have a market capitalization of about $650 million. That's 1.7 times trailing revenue. Yoox trades at 1.3 times, as does $65 billion JD, which is also unprofitable using conventional American accounting guidelines.
In addition to its squeaky-clean image and extravagant clientele, Secoo is in a sweet spot. Consultancy Bain expects the market in which Secoo focuses to be the fastest-growing segment of China's luxury industry in coming years. That's one reason why deeper-pocketed Alibaba and JD are chasing high-end consumers, too.
Jack Ma's$450 billion colossus, however, is plagued by a reputation of having dodgy wares on its sites, which partly explains why only about a fifth of luxury brands are willing to set up shop on its Tmall, according to research outfit L2. JD, meanwhile, needs to reposition its mass-market image. Secoo, therefore, could make a tempting target for either company, and that is just one more reason why its shares may be a premium purchase.

Wednesday, September 20, 2017

Krystal Biotech (KRYS) started trading on the Nasdaq on 20 Sept 2017

The Pittsburgh-based gene therapy company, which develops treatments for dermatological diseases, upped its offering to 3.96 million shares at $10 a share to raise up to $39.6 million. An additional 594,000 shares are available to cover overallotments. Last week, Krystal's Securities and Exchange Commission filing offered 3 million shares at a price range of $9 to $11 a share. In late August, Krystal Biotech said it hoped to raise up to $35 million in its IPO.


Krystal Biotech is a gene therapy company that is looking to bring products developed via its gene platform to the commercial market.

The company plans “to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene, and plan to leverage our platform to expand our pipeline to include other dermatological indications in the future,” it said in its IPO filing.

The company’s leading product is known as KB103 and uses gene therapy to treat a rare genetic skin disease, dystrophic epidermolysis bullosa (DEB).

The disease currently has no approved treatment and those with it are often called “butterfly children” because the skin appears as fragile as butterfly wings.

KB103 is not yet in clinical trials.

The severest form of DEB is recessive DEB (RDEB), which “is characterized by severe skin blistering, extremely fragile skin, mutilating scarring of the hands and feet, joint contractures, strictures of the esophagus, and often, eventually the development of aggressive squamous cell carcinomas which may shorten the patient’s life,” the company said.

“Nearly 10% of RDEB patients die before the age of 10, almost 40% die by the age of 20, and over 70% die before the age of 30,” Krystal Biotech said.


Just One Gene Therapy Product Has the FDA’s OK

The market for the treatment would be 125,000 global patients, the company said, citing DEBRA International. There are about 3,200 to 3,500 patients in the U.S., European Union, Japan and Canada.

But here’s the big warning with the market opportunity for a gene therapy company.

“To date, only one gene therapy product has received marketing authorization from the FDA, and only two gene therapy products have received marketing authorization from the EMA,” Krystal Biotech said.

Monday, September 18, 2017

Nabriva Therapeutics (NBRV) : positive trial of pneumonia treatment

  • www.nabriva.com
  • HQ: Dublin,  Ireland
  • Founded in 2006
  • IPO in 2015
  • 59 Employees


The company reported positive results from a late-stage trial of a treatment for community-acquired bacterial pneumonia, or CABP, the leading cause of infectious death in the U.S. The Dublin, Ireland-based company said its intravenous to oral lefamulin met its primary endpoint. "These Phase 3 data provide strong evidence of the potential of lefamulin to treat adults with CABP and provide an alternative to a current gold standard treatment regimen," Nabriva Chief Executive Dr. Colin Broom said in a statement. The company is currently completing enrollment for a second phase 3 trial of the drug and expects to have topline data ready by spring of 2018. The stock has gained 15% in 2017 through Friday, while the S&P 500 (SPX) has gained about 12%.

********

Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of novel antibiotics to treat serious bacterial infections with a focus on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, a novel semi-synthetic pleuromutilin antibiotic for systemic administration in humans. The company’s product, lefamulin is being studied in two registrational Phase 3 clinical trials in patients with moderate to severe community-acquired bacterial pneumonia. It is also developing lefamulin that has completed Phase 2 clinical trial for the treatment of acute bacterial skin and skin structure infections, as well as in preclinical studies for antibacterial activity against various gram-positive bacteria, gram-negative bacteria, and atypical bacteria, including multi-drug resistant strains. In addition, the company is developing BC-7013, a topical pleuromutilin product candidate, which has completed a Phase 1 clinical trial for the treatment of various gram-positive infections, including uncomplicated skin and skin structure infections. Nabriva Therapeutics plc was founded in 2006 and is based in Dublin, Ireland.

** charts before ** 





Friday, September 15, 2017

Long trade : AMC +17% (9/17)

  • 11 Sept:  #97, $14,  vol. 2.3 M
  • 15 Sept:  $16.50     +17%

 



Long trade : EROS +50% (9/17)

  • 23 Aug.:  vol. 877K,,  $800
  • 1 Sept:  vol.  2.3 M,  $13     +50%



 



Tuesday, September 12, 2017

Intercept Pharmaceuticals (ICPT) : issues warning regarding Ocaliva

** charts before warning**

  

** charts after warning**

  



Intercept Pharmaceuticals (ICPT) dove Tuesday after the firm issued a letter warning physicians against overdosing some patients with Ocaliva, which has been tied to liver injuries and death.

In early trading on the stock market today, Intercept toppled 18%, near 93.10. Shares hit their lowest point in 19 months. More broadly biotech stocks dipped 1.4%.

The letter warned physicians about post-marketing cases of liver injury, liver decompensation, liver failure and deaths in patients with liver impairment and a rare disease known as primary biliary cholangitis who receive Ocaliva more frequently than recommended.

"In addition, serious liver adverse events have been reported in patients initiating therapy without cirrhosis or with mild liver impairment," Intercept said in its letter. "Liver-related adverse events have occurred both early in treatment and after months of treatment."

Current Ocaliva dosing recommendations are for 5 milligrams once a week in primary biliary cholangitis patients with liver impairment. Primary biliary cholangitis is a chronic liver disease resulting from the progressive destruction of bile ducts in the liver.

The warning could weigh on Ocaliva sales and help eventual sales of seladelpar, a treatment from CymaBay Therapeutics (CBAY) that is being investigated in primary biliary cholangitis, says Leerink analyst Joseph Schwartz. Seladelpar has a different mechanism and better safety profile.

"Further down the road, if others such as etrasimod (from Arena Pharmaceuticals (ARNA)) can show competitive (effectiveness) and safety profile, Ocaliva could face competition on multiple fronts, thereby increasing the important of Ocaliva's prospects in nonalcoholic steatohepatitis," he said.

Schwartz reiterated outperform ratings on CymaBay and Arena stocks. He rates Intercept at market perform.

He notes the warnings regarding liver injury and death were included on Ocaliva's label for some patients with liver impairment. These issues were also raised at the advisory committee meeting. Still, the safety notice is a headwind for Ocaliva's base business, he said in a note to clients.

"Intercept has enjoyed a robust launch trajectory to date," he said. "In the second quarter, however, management's more tempered expectation for the remainder of 2017 increased investor caution and the stock has accordingly been weak."

He added: "Today's letter/disclosure, in our view, will likely add another layer of caution as physicians may find Ocaliva dosing more cumbersome and patients more reluctant to initiate therapy."